Salmeterol-Fluticasone: The Role Revisited

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Asthma and COPD often coexist, creating an overlap phenotype with higher exacerbation rates.
• Diagnosis of COPD can be delayed due to limited spirometry access, particularly in biomass smoke-exposed populations.
• Asthma COPD overlap phenotype presents unique management challenges, necessitating effective treatment strategies.

Purpose of the Study:

• To evaluate the efficacy and safety of salmeterol-fluticasone combination (SFC) in managing asthma, COPD, and asthma COPD overlap phenotype.
• To assess the role of eosinophilia as an indicator for initiating ICS/LABA therapy.
• To determine the cardiovascular safety of SFC in patients with COPD and co-existing cardiovascular diseases.

Main Methods:

• Review of existing studies on SFC efficacy in asthma and COPD.
• Analysis of cardiovascular safety data for salmeterol and SFC from clinical trials like TORCH.
• Expert advisory board discussion on clinical experience with SFC in various respiratory conditions.

Main Results:

• SFC improves airflow limitation and reduces exacerbations in asthma, COPD, and asthma COPD overlap phenotype.
• Evidence of eosinophilia supports the use of ICS/LABA combinations.
• Salmeterol and SFC demonstrate cardiovascular safety, with no increased risk of adverse events and potential cardio-protective effects.

Conclusions:

• SFC is a beneficial treatment for stable, uncontrolled asthma, asthma COPD overlap phenotype, and COPD.
• The cardiovascular safety of salmeterol in COPD patients is established, outweighing concerns about its onset of action.
• SFC offers significant benefits for high-risk patients, including those with asthma COPD overlap, elevated eosinophils, and pre-existing cardiovascular disease.